INSM - Insmed Inc. (INSM) Q1 2024 Earnings Call Transcript
2024-05-09 16:29:09 ET
Insmed, Inc. (INSM)
Q1 2024 Earnings Conference Call
May 09, 2024, 08:00 ET
Company Participants
Bryan Dunn - Executive Director, Investor Relations
William Lewis - Chairman, President & CEO
Eugene Sullivan - Chief Product Strategy Officer & Chief Scientific Officer
Sara Bonstein - CFO
Conference Call Participants
Andrea Tan - Goldman Sachs & Co.
Jessica Fye - JPMorgan Securities
Leon Wang - Barclays Capital
Joseph Schwartz - Leerink Partners
Nicole Germino - Truist Securities
Jason Zemansky - Bank of America Merrill Lynch
Ritu Baral - Cowen & Co.
Jeff Hung - Morgan Stanley
Liisa Bayko - Evercore ISI
Jennifer Kim - Cantor Fitzgerald
Stephen Willey - Stifel
Presentation
Operator
Thank you for standing by. My name is Dee, and I will be your conference operator today. At this time, I would like to welcome everyone to the Insmed's First Quarter 2024 Financial Results Call. [Operator Instructions].
I would now like to turn the call over to Bryan Dunn, Head of Investor Relations.
Bryan Dunn
Thank you, Dee. Good day, everyone, and welcome to today's conference call to discuss Insmed's first quarter 2024 financial results and provide a business update. I am joined today by Will Lewis, Chair and Chief Executive Officer; Gene Sullivan, Chief Product Strategy Officer; and Sara Bonstein, Chief Financial Officer, who will each provide prepared remarks before we open it up for your questions.
Before we start, please note that today's call will include forward-looking statements based on our current expectations. These statements represent our judgment as of today and inherently involve risks and uncertainties that may cause actual results to differ materially from the results discussed. Please refer to our filings with the Securities and Exchange Commission for more information concerning the risk factors that could affect the Company.
Also note that our call today will include blinded observations from our ongoing Phase 2 study of TPIP in pulmonary arterial hypertension. These observations may not be representative of results once the study is completed and all data is collected and analyzed as a result, any future interim data readouts and the final data from this study may be materially different than the observations described today.
Finally, the information on today's call is for the benefit of the investment community. It is not intended for promotional purposes, and it is not sufficient for prescribing decisions.
I will now turn the call over to Will Lewis for prepared remarks.
William Lewis
Thank you, Bryan, and welcome, everyone. Today we intend to review the progress from three of the company's main programs: ARIKAYCE, TPIP, and brensocatib. Let's begin with TPIP
The first of this quarter's two important data readouts came this morning with the announcement of the top line results from our Phase 2 study, examining TPIP in patients with pulmonary hypertension associated with interstitial lung disease as well as an update of blinded data from our ongoing Phase 2 study in pulmonary arterial hypertension in a moment, Jim Sullivan will review these data in greater detail, but let me just say that we couldn't be more pleased with the progress and the clinical results that continue to come from this exciting program.
Turning to brensocatib, the highly anticipated top-line release of the Phase 3 ASPEN trial remains on track to readout in the second half of this quarter. Let me take one additional moment to touch on the detailed events and timelines relating to brensocatib. At the end of March, all adult patients in ASPEN have completed their 52-week visit which is the point at which the primary and secondary efficacy endpoints are measured in the trial....
Insmed, Inc. (INSM) Q1 2024 Earnings Call Transcript